
## Sravanti Rangaraju

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10259673/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia. Leukemia Research, 2022, 117, 106844.	0.8	7
2	Safe and Effective Use of Imatinib to Treat Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Pregnancy. Journal of Adolescent and Young Adult Oncology, 2022, , .	1.3	2
3	IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia. Cancer Treatment and Research Communications, 2022, 31, 100560.	1.7	2
4	Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia. British Journal of Haematology, 2022, , .	2.5	1
5	A phase 1 study of NTX-301, an oral DNMT1 inhibitor, in patients with MDS and AML (trial in progress) Journal of Clinical Oncology, 2022, 40, TPS7077-TPS7077.	1.6	1
6	Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML. Blood, 2018, 132, 3949-3949.	1.4	0
7	Abstract 800: Exploiting the proteasome to overcome RAS and WT1 mutation mediated resistance to FLT-3 inhibition in acute myeloid leukemia. , 2020, , .		0
8	Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents Journal of Clinical Oncology, 2022, 40, e18808-e18808.	1.6	0